We will absolutely need to continue our endeavors to evaluate reliable predictive biomarkers for both targeted drugs and immunotherapeutic agents to achieve a truly personalized melanoma therapy with the maximal clinical benefit.
Kevin B. Kim, MD
Advertisement
Articles by Kevin B. Kim, MD
Advertisement
Latest Updated Articles
- The Past, Present, and Future of Melanoma Therapy
May 15th 2013
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
2
What Are The Top Lymphoma Abstracts at ASCO 2026?
3
ASCO 2026: Key Genitourinary Oncology Trials to Watch For
4
How the Landscape of GI Oncology is Evolving: A 2026 ASCO Preview
5